Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: The PIILR extension study

Don E. Smith, Andrew Carr, Matthew Law, Allison Martin, Jeff Hudson, Jennifer Hoy, David A. Cooper

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)


Eighteen patients with HIV lipoatrophy, receiving quadruple reverse transcriptase-inhibitor therapy including stavudine or zidovudine, were randomly assigned to continue current therapy or stop stavudine/zidovudine. After 24 weeks more limb fat had recovered in the stop than in the continue group; however, five of the stop subjects experienced virological failure. The withdrawal of thymidine analogues from a protease inhibitor-sparing regimen can improve peripheral fat, but compromises virological control.

Original languageEnglish
Pages (from-to)2489-2491
Number of pages3
Issue number18
Publication statusPublished - 6 Dec 2002

Cite this